CDK4 and non-small cell lung carcinoma: Mechanistically, the functional consequences of CDK4/6 inhibition apart from cell cycle arrest in NSCLC are largely unknown; yet, metabolic reprogramming in response to palbociclib has revealed unique targetable vulnerabilities in several cancers including pancreatic, colorectal, and leukemia [14–16].